KKR deducts $400 million in deals to control shares of Indian cancer hospital chain HCG: Details – KKR (NYSE: KKR)

On Sunday, KKR&Co. Inc. KKR and CVCa private marketing manager, became the largest shareholder of Healthcare Global Enterprise (HCG) and has full operational control for $400 million.

As part of the agreement, KKR will acquire up to 54% of the HCG equity stake from CVC Asia V at a price of INR 445 per share (approximately US$5.13).

Under SEBI’s acquisition regulations, KKR will also issue public offers to public shareholders and increase its ownership to 54%-77% after the transaction is completed.

The transaction is expected to close in the third quarter of 2025, with pending regulatory approvals and standard closure conditions.

Read: KKR offers bids in Fuji Soft’s fierce takeover, Bain weighs next: Report

Akshay TannaKKR, Partner and Head of Private Equity in India, said: “As healthcare continues to be the theme focus of KKR in India, our investment in HCG will support the development of healthcare infrastructure and critical oncology services and take care of more patients in the country. .”

It is worth noting that KKR is strengthening its focus on the Indian health care sector through its Asian IV investment. Its past investments include Baby Memorial Hospital, Healthium, Infinx, Max Healthcare, JB and Gland Pharma, Spanning Hospitals, medical devices, healthcare technologies and medicines.

Last week, KKR reached an agreement Eni Spa Expand its ownership hostility By obtaining an additional 5% stake, worth 587.5 million euros (approximately US$614.4 million).

KKR had cash and cash equivalents of $8.54 billion as of the fourth quarter.

Investors can pass FM Focus Equity ETF FMCX and Private equity ETFs listed by EA Series Trust Whitewolf LBO.

Price action: KKR shares fell $132.22 on Friday, down 1.73%.

Read the next article:

Photos by Shutterstock.